Home > Analytics > NATCO PHARMA

NATCO PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 524816     NSE : NATCOPHARM    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward
Pledged Shares : None or < 25%
Sep 25,2023
Price(EOD): ₹ 848.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 15,202.01 Cr
Value of ₹ 1 Lac invested in NATCO PHARMA
on Sep 25,2018 (price: ₹ 751.45)

₹ 1 L

₹ 1.13 L

1W : -2.2% 1M : -4.8% 1Y : 31.1%
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results
NATCO PHARMA is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Industry Peers & Returns1W1M1Y
NATCO PHARMA -2.2% -4.8% 31.1%
SUN PHARMACEUTICAL INDUSTRIES -2.1% 0.6% 23.6%
DIVIS LABORATORIES -1.4% 2% 2%
CIPLA -5% -3.3% 8.7%
DR REDDYS LABORATORIES -5% -7.9% 30.8%
TORRENT PHARMACEUTICALS -2% -5.8% 22.5%
ABBOTT INDIA -2.8% -2.2% 24.5%
ZYDUS LIFESCIENCES -6.4% -6% 60.7%
ALKEM LABORATORIES -2.9% -4.3% 6.8%

FUNDAMENTAL ANALYSIS OF NATCO PHARMA

 
Fundamentals Score
[ Q(TTM): Jun2023, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF NATCO PHARMA

 
Valuation Score
[As on : Sep 25,2023 ]

Ratio Consolidated
P/E
P/B
P/S
18.65
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 815.20 Cr
[Latest Qtr - Jun2023 - Consolidated Results ]

3.12
P/B Calculated based on Book Value of Rs 4,873.80 Cr
[Latest Year - Mar2023 - Consolidated Results ]

5.13
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 2,963.00 Cr
[Latest Qtr - Jun2023 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 15% undervalued companies ! Discover More →

FAIR VALUE OF NATCO PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
299%
34%
74%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF NATCO PHARMA



NATCO PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF NATCO PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0.09
0.06
0.08
0.08
0.09
0.06
0.08
0.08
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF NATCO PHARMA

Pledged Promoter Shares
0 %
As on : Jun2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF NATCO PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
27.02%
55.71%
54.13%
52.39%
28.93%
33.57%
29.6%
31.18%
QtrlyTrend
8
Latest Qtr: Jun2023
Quarterly Result Analysis →


NATCO PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE MIDSMALLCAP -1.6% 3.3% 26.5%
S&P BSE 400 MIDSMALLCAP -1.7% 3% 25.6%
S&P BSE 250 SMALLCAP -1.9% 3.5% 28.3%
S&P BSE SMALL CAP -1.9% 2.9% 27.3%
S&P BSE ALLCAP -2.2% 1.9% 13.3%
NSE Indices1W1M1Y
NIFTY MID SMALL400 -1.4% 3.8% 26.9%
NIFTY500 MULTICAP 50:25:25 -2% 2.6% 17.9%
NIFTY SMALLCAP250 -2.1% 4% 28.2%
NIFTY 500 -2.2% 1.9% 12.9%
NIFTY PHARMA -3.6% -1.7% 21.4%

You may also like the below Video Courses


FAQ about NATCO PHARMA


Is NATCO PHARMA good for long term investment?

As on Sep 25,2023, the Fundamentals of NATCO PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of NATCO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is NATCO PHARMA UnderValued or OverValued?

As on Sep 25,2023, NATCO PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of NATCO PHARMA ?

As on Sep 25,2023, the Intrinsic Value of NATCO PHARMA is Rs. 486.43 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 212.64
Fair Value [Median EV / Sales Model] : Rs. 633.63
Fair Value [Median Price / Sales Model] : Rs. 486.43
Estimated Median Fair Value of NATCO PHARMA : Rs. 486.43

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is NATCO PHARMA trading at a Premium or Discount?

As on Sep 25,2023, NATCO PHARMA is trading at a Premium of 74% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].